Outcomes with nifedipine GITS or Co-amilozide in hypertensive diabetics and nondiabetics in intervention as a goal in hypertension (INSIGHT)

  • Mancia G
  • Brown M
  • Castaigne A
 et al. 
  • 28


    Mendeley users who have this article in their library.
  • 142


    Citations of this article.


To investigate the impact of treatment on cardiovascular mortality and morbidity, we assessed outcomes in patients with hypertension and diabetes who received co-amilozide or nifedipine in the International Nifedipine GITS Study: Intervention as a Goal in Hypertension. Participants had to be 55 to 80 years of age, with hypertension (> or =150/95 or > or =160 mm Hg) and at least one additional cardiovascular risk factor. Patients received 30 mg nifedipine once daily or co-amilozide (25 mg hydrochlorothiazide and 2.5 mg amiloride) daily. Doses were doubled if target blood pressures (

Author-supplied keywords

  • Calcium channel blockers
  • Diabetes mellitus
  • Diuretics
  • Morbidity
  • Mortality
  • Nifedipine

Get free article suggestions today

Mendeley saves you time finding and organizing research

Sign up here
Already have an account ?Sign in

Find this document


Cite this document

Choose a citation style from the tabs below

Save time finding and organizing research with Mendeley

Sign up for free